A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia

doi:10.1017/S1461145709990939

機構典藏 > College of Sciences > Department of Applied Mathematics and Data Science > Journal Article > Item 987654321/58682

Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/58682

Title:	A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
Authors:	Lane, Hsien-Yuan;Lin, Ching-Hua;Huang, Yu-Jhen;Liao, Chun-Hui;Chang, Yue-Cune;Tasi, Guochuan E.
Contributors:	淡江大學數學學系
Keywords:	D-serine;glycine;N-methylglycine;NMDA;sarcosine;schizophrenia
Date:	2010-05
Issue Date:	2011-10-01 21:03:01 (UTC+8)
Publisher:	Cambridge: Cambridge University Press
Abstract:	Recent evidence indicates that enhancing N-methyl-D-aspartate (NMDA) neurotransmission with the treatment of NMDA/glycine site agonists, such as D-serine, or a glycine transporter-1 (GlyT-1) antagonist, N-methylglycine (sarcosine), can improve symptoms of schizophrenia. To compare these two novel approaches, 60 patients with chronic schizophrenia were enrolled into a 6-wk double-blind, placebo-controlled trial of add-on treatments at the reported effective dosages (2 g/d). Clinical assessments were conducted every other week. Treatment group x treatment duration interaction analysis by multiple linear regression showed that sarcosine was superior to placebo at all four outcome measures of Positive and Negative Syndrome Scale (PANSS) total (p=0.005), Scale for the Assessment of Negative Symptoms (SANS) (p=0.021), Quality of Life (QOL) (p=0.025), and Global Assessment of Functioning (GAF) (p=0.042). However, d-serine did not differ significantly from placebo in any measure. Sarcosine treatment was better than d-serine in effect sizes for all outcome measures. Sarcosine also surpassed placebo in most of the measures of five PANSS factors and five SANS subscales. All treatments were well tolerated. These findings suggest that the GlyT-1 inhibitor is more efficacious than the NMDA/glycine site agonist in treatment for schizophrenia, including life quality and global function, at the dosages tested.
Relation:	International Journal of Neuropsychopharmacology 13(4), pp.451-460
DOI:	10.1017/S1461145709990939
Appears in Collections:	[Department of Applied Mathematics and Data Science] Journal Article

Files in This Item:

File	Description	Size	Format
1461-1457_13(4)p451-460.pdf		8476Kb	Adobe PDF	354	View/Open
index.html		0Kb	HTML	254	View/Open

Loading...